---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000595"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-04-21T23:59:59+00:00"
generated_at: "2026-06-16T21:31:34.772486+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Arcturus Therapeutics enters $50M revolving credit facility with Wells Fargo

## Summary
- Credit agreement with Wells Fargo for $50M revolving line; two-year term, renewable annually.
- Borrowings bear interest at SOFR +1.00%; default rate +2.00%.
- No prepayment penalty; collateral of $55M in cash pledged.
- Commitment fee of 0.25% of loan amount for each renewal.

## SEC filing metadata
- accession: 0001193805-23-000595
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-04-21T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000595/0001193805-23-000595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000595/e618524_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000595
- JSON: https://secwatch.observer/filing/0001193805-23-000595.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000595.txt

## Key facts
- Debt Financings
  Arcturus Therapeutics Holdings Inc. incurred revolving credit of $50 million revolving credit line with Wells Fargo Bank, National Association at 1.00% above either the Daily Simple SOFR or Term SOFR maturing two years.
  - Instrument: revolving credit
  - Principal: $50 million revolving credit line
  - Counterparty: Wells Fargo Bank, National Association
  - Rate: 1.00% above either the Daily Simple SOFR or Term SOFR
  - Maturity: two years
  - Event: incurrence
  source text: On April 21, 2023, Arcturus Therapeutics, Inc. (“Borrower”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc. (the “Company”, and together with Borrower, “Arcturus”), entered into a credit agreement (the “Credit Agreement”) Wells Fargo Bank, National Association (“Wells Fargo”) whereby Wells Fargo will make a $50 million revolving credit line available to Arcturus (the “Loan”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523000595/0001193805-23-000595-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.